CN1942475A - 作为Tie2抑制剂的取代的噻吩并[2,3－d]吡啶和噻唑并[2,3－d]吡啶 - Google Patents

作为Tie2抑制剂的取代的噻吩并[2,3－d]吡啶和噻唑并[2,3－d]吡啶 Download PDF

Info

Publication number
CN1942475A
CN1942475A CNA2005800119556A CN200580011955A CN1942475A CN 1942475 A CN1942475 A CN 1942475A CN A2005800119556 A CNA2005800119556 A CN A2005800119556A CN 200580011955 A CN200580011955 A CN 200580011955A CN 1942475 A CN1942475 A CN 1942475A
Authority
CN
China
Prior art keywords
formula
methyl
imidazol
pyrimidin
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2005800119556A
Other languages
English (en)
Chinese (zh)
Inventor
C·D·琼斯
R·W·A·卢克
W·麦库尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of CN1942475A publication Critical patent/CN1942475A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Reproductive Health (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CNA2005800119556A 2004-02-05 2005-02-01 作为Tie2抑制剂的取代的噻吩并[2,3－d]吡啶和噻唑并[2,3－d]吡啶 Pending CN1942475A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0402518.5 2004-02-05
GBGB0402518.5A GB0402518D0 (en) 2004-02-05 2004-02-05 Therapeutic agents

Publications (1)

Publication Number Publication Date
CN1942475A true CN1942475A (zh) 2007-04-04

Family

ID=31985686

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2005800119556A Pending CN1942475A (zh) 2004-02-05 2005-02-01 作为Tie2抑制剂的取代的噻吩并[2,3－d]吡啶和噻唑并[2,3－d]吡啶

Country Status (9)

Country Link
US (1) US7476677B2 (enExample)
EP (1) EP1716155B1 (enExample)
JP (1) JP2007520536A (enExample)
CN (1) CN1942475A (enExample)
AT (1) ATE387453T1 (enExample)
DE (1) DE602005005024T2 (enExample)
ES (1) ES2300977T3 (enExample)
GB (1) GB0402518D0 (enExample)
WO (1) WO2005075483A1 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102250112A (zh) * 2010-05-18 2011-11-23 上海再启生物技术有限公司 7-溴-4-氨基噻吩并嘧啶的制备方法
CN102725296A (zh) * 2010-01-29 2012-10-10 韩美科学株式会社 对蛋白激酶有抑制活性的噻吩并[3,2-d]嘧啶衍生物
CN104039798A (zh) * 2011-12-30 2014-09-10 韩美药品株式会社 具有蛋白激酶抑制活性的噻吩并[3,2-d]嘧啶衍生物

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2671891A3 (en) 2008-06-27 2014-03-05 Amgen Inc. Ang-2 inhibition to treat multiple sclerosis
US20100093714A1 (en) * 2008-10-13 2010-04-15 Devraj Chakravarty AMIDES OF THIENO[2,3-d]PYRIMIDINE AND THEIR USE AS ADENOSINE A2a RECEPTOR ANTAGONISTS
TWI492949B (zh) * 2010-06-09 2015-07-21 Abbvie Bahamas Ltd 結晶型激酶抑制劑
WO2011156473A1 (en) * 2010-06-09 2011-12-15 Abbott Laboratories Crystalline forms of kinase inhibitors
TWI482770B (zh) * 2010-06-09 2015-05-01 Abbvie Bahamas Ltd 結晶型激酶抑制劑

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999058523A1 (en) 1998-05-14 1999-11-18 G.D. Searle & Co. 1,5-DIARYL SUBSTITUTED PYRAZOLES AS p38 KINASE INHIBITORS
GB0102687D0 (en) * 2001-02-02 2001-03-21 Pharmacia & Upjohn Spa Oxazolyl-pyrazole derivatives active as kinase inhibitors,process for their preparation and pharmaceutical compositions comprising them
WO2003022852A2 (en) * 2001-09-11 2003-03-20 Smithkline Beecham Corporation Furo-and thienopyrimidine derivatives as angiogenesis inhibitors
ATE374753T1 (de) 2001-12-21 2007-10-15 Vernalis Cambridge Ltd 3-(2,4)dihydroxyphenyl-4-phenylpyrazole und deren medizinische verwendung
US7560552B2 (en) * 2002-03-21 2009-07-14 Abbott Laboratories Thiopyrimidine and isothiazolopyrimidine kinase inhibitors
US7427616B2 (en) 2002-08-06 2008-09-23 Astrazeneca Ab Condensed pyridines and pyrimidines with tie2 (TEK) activity

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102725296A (zh) * 2010-01-29 2012-10-10 韩美科学株式会社 对蛋白激酶有抑制活性的噻吩并[3,2-d]嘧啶衍生物
CN102725296B (zh) * 2010-01-29 2015-04-01 韩美科学株式会社 对蛋白激酶有抑制活性的噻吩并[3,2-d]嘧啶衍生物
CN102250112A (zh) * 2010-05-18 2011-11-23 上海再启生物技术有限公司 7-溴-4-氨基噻吩并嘧啶的制备方法
CN104039798A (zh) * 2011-12-30 2014-09-10 韩美药品株式会社 具有蛋白激酶抑制活性的噻吩并[3,2-d]嘧啶衍生物
CN104039798B (zh) * 2011-12-30 2016-08-24 韩美药品株式会社 具有蛋白激酶抑制活性的噻吩并[3，2-d]嘧啶衍生物

Also Published As

Publication number Publication date
ES2300977T3 (es) 2008-06-16
DE602005005024D1 (de) 2008-04-10
WO2005075483A1 (en) 2005-08-18
US7476677B2 (en) 2009-01-13
EP1716155B1 (en) 2008-02-27
ATE387453T1 (de) 2008-03-15
DE602005005024T2 (de) 2009-03-12
US20070135455A1 (en) 2007-06-14
EP1716155A1 (en) 2006-11-02
JP2007520536A (ja) 2007-07-26
GB0402518D0 (en) 2004-03-10

Similar Documents

Publication Publication Date Title
CN1193026C (zh) 2－吡唑啉－5－酮
KR101410902B1 (ko) 암 치료에 유용한 egfr 조절물질로서 2-(2,4,5-치환된-아닐리노)피리미딘 유도체
CN1137100C (zh) 能够抑制表皮生长因子受体族之酪氨酸激酶的三环化合物
CN1063446C (zh) 作为促性腺激素释放激素拮抗剂的噻吩并吡啶衍生物
CN1433405A (zh) 喹唑啉化合物
EA018708B1 (ru) ПРОИЗВОДНЫЕ МОРФОЛИНОПИРИМИДИНА, ИСПОЛЬЗУЕМЫЕ ПРИ ЗАБОЛЕВАНИЯХ, СВЯЗАННЫХ С mTOR КИНАЗОЙ И/ИЛИ PI3K
JP2020526543A (ja) ロイシンリッチリピートキナーゼ２の阻害剤
CN1370163A (zh) 咪唑并[1,2－a]吡啶和吡唑并[2,3－a]吡啶衍生物
CN1349528A (zh) 嘧啶化合物
CN1422262A (zh) 2－苯并噻唑基脲衍生物及其作为蛋白激酶抑制剂的应用
CN1681818A (zh) 氮杂吲哚激酶抑制剂
CN1636005A (zh) 苯并噻嗪酮和苯并噁嗪酮化合物
CN1446212A (zh) 具有vegf抑制活性的喹啉衍生物
CN1976919A (zh) 作为erk蛋白激酶抑制剂的吡咯化合物、它们的合成和中间体
CN1820009A (zh) 作为激酶抑制剂的吡咯并[3,4－c]吡唑衍生物
JP2007517006A (ja) Ｔｉｅ２（ｔｅｋ）活性のあるピリミジン
CN1751052A (zh) 治疗药物
BR112019015278A2 (pt) compostos
JP2020506966A (ja) 化合物
CN1347416A (zh) 取代的3－氰基－[1.7],[1.5]和[1.8]－二氮杂萘酪氨酸激酶抑制剂
AU2014347126A1 (en) Pyrido[2,3-d]pyrimidin-4-one compounds as tankyrase inhibitors
CN1942475A (zh) 作为Tie2抑制剂的取代的噻吩并[2,3－d]吡啶和噻唑并[2,3－d]吡啶
US20080146599A1 (en) Pyrimidine Compounds Having Tie-2 (Tek) Inhibitory Activity
CN1863794A (zh) 作为血管生成抑制剂的喹唑啉衍生物
CN101056639A (zh) 噻唑并吡啶激酶抑制剂

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Open date: 20070404